P-OTC-101 / Roche - LARVOL DELTA

Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update (PRNewswire) - "Poseida Therapeutics, Inc...today announced a $50 million strategic investment by Astellas, which is comprised of the purchase of 8,333,333 shares of common stock at $3.00 per share for an aggregate purchase price of $25 million and an additional $25 million one-time payment for certain strategic rights, and provided a business update...'Based on these findings, we are adjusting guidance on data updates and look forward to sharing clinical data highlighting some of these enhancements at a medical meeting later this year, with plans for a more robust clinical update to follow in mid-2024'....Poseida expects to dose the first patient with P-CD19CD20-ALLO1 in early 2024."

Clinical • Trial status • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor